GABA transporter (GAT) neurons are inhibitory neurons that express the plasma membrane GABA transporters responsible for terminating synaptic GABA signaling. These transporters—GAT-1 (SLC6A1), GAT-2 (SLC6A11), GAT-3 (SLC6A12), and the betaine/GABA transporter BGT-1 (SLC6A12)—are expressed on GABAergic neurons, astrocytes, and presynaptic terminals. GAT-mediated GABA clearance is essential for proper inhibitory tone, and transporter dysfunction contributes to epileptogenesis, cognitive impairment in Alzheimer's disease, motor dysfunction in Parkinson's disease, and network hyperexcitability in amyotrophic lateral sclerosis. [1]
| Transporter | Gene | Cellular Expression | Brain Distribution | Function | [2]
|-------------|------|--------------------|--------------------|----------| [3]
| GAT-1 | SLC6A1 | Neurons (axons), Astrocytes | Neocortex, hippocampus, cerebellum, basal ganglia | Primary neuronal GABA clearance | [4]
| GAT-2 | SLC6A13 | Astrocytes | Ependyma, meninges, retina | GABA uptake from CSF | [5]
| GAT-3 | SLC6A11 | Astrocytes | Neocortex, hippocampus, thalamus | Astrocytic GABA clearance | [6]
| BGT-1 | SLC6A12 | Astrocytes, Neurons | Cerebral cortex | Osmoregulation, GABA transport | [7]
GABA transporters are Na+/Cl--coupled symporters:
Transport stoichiometry: 1 GABA + 2 Na+ + 1 Cl- → intracellular
Reversal: Under pathological depolarization, transporters can run in reverse, releasing GABA
GAT-1 is the primary neuronal GABA transporter:
GAT-1 is expressed in specific inhibitory neuron populations:
| Neuron Type | GAT-1 Location | Function |
|---|---|---|
| PV+ Interneurons | Axon terminals, perisynaptic | Rapid GABA clearance, phasic inhibition |
| SST+ Interneurons | Dendrites, soma | Spillover control, tonic inhibition |
| VIP+ Interneurons | Moderate expression | Modulates disinhibitory circuits |
| Cerebellar Purkinje cells | Axon terminals | Clears GABA from recurrent collaterals |
Astrocytes express GAT-3 as the primary GABA transporter:
GAT dysfunction contributes to epileptogenesis:
Genetic causes:
Pathophysiological cascade:
Therapeutic implications:
GABAergic dysfunction in AD involves altered transporter expression:
Basal ganglia GABAergic circuitry is altered in PD:
| Region | GAT Change | Functional Consequence |
|---|---|---|
| Striatum | GAT-1 ↓ | Reduced GABA clearance, altered MSN firing |
| Globus pallidus | GAT-1 ↑ | Enhanced inhibition, hypokinetic features |
| Subthalamic nucleus | GAT-1 ↓ | Increased inhibition, oscillations |
Therapeutic considerations:
Cortical hyperexcitability in ALS involves GABAergic changes:
GAT expression is altered in HD:
| Drug | GAT Target | Mechanism | Clinical Use |
|---|---|---|---|
| Tiagabine | GAT-1 (selective) | Blocks GABA uptake → increases synaptic GABA | Partial seizures (adjunctive) |
| Valproate | Indirect GAT effect | Increases GABA synthesis and release | Broad spectrum AED |
| Vigabatrin | GABA-T (not GAT) | Blocks GABA degradation | Infantile spasms, partial seizures |
CSF GABA: Indirect measure of GABA metabolism
SLC6A1 sequencing: Genetic diagnosis of epilepsy syndromes
Neurons Major brain cell type
Glia — Suppor- Alzheimer's DiseaseAlzhe- Parkinson's Diseased neurodegenerative disease
Parkinson's Disease Related neurodegenerative disease
Madsen et al. GABA transporter molecular biology (2011). 2011. ↩︎
[Borden, GABA transporter pharmacology (1996)](https://doi.org/10.1016/S0024-3205(96). 1996. ↩︎
Carvill et al. SLC6A1 mutations in epilepsy (2015). 2015. ↩︎
Wu et al. GAT-1 in Alzheimer's disease (2014). 2014. ↩︎
Chen et al. GABA transporters in Parkinson's disease (2016). 2016. ↩︎
Turner et al. Cortical hyperexcitability in ALS (2005). 2005. ↩︎